Alkermes Plc (NASDAQ:ALKS) gets upgraded to Neutral by Goldman Sachs Group

ME Staff
-
0

Analyst Ratings For Alkermes Plc (NASDAQ:ALKS)

Today, Alkermes Plc (NASDAQ:ALKS) stock received an upgrade by Goldman Sachs Group from Sell to Neutral.

There are 7 Hold Ratings, 3 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Alkermes Plc (NASDAQ:ALKS) is Hold with a consensus target price of $37.00 per share, a potential 64.23% upside.

Some recent analyst ratings include

  • 7/15/2019-Alkermes Plc (NASDAQ:ALKS) gets upgraded to Neutral by Goldman Sachs Group
  • 5/31/2019-Alkermes Plc (NASDAQ:ALKS) has coverage initiated with a Neutral ➝ Neutral rating and $28.00 price target
  • 5/1/2019-Alkermes Plc (NASDAQ:ALKS) gets downgraded to Neutral by Citigroup with a price target of $33.00
  • 4/10/2019-Alkermes Plc (NASDAQ:ALKS) had its Buy rating reiterated by JPMorgan Chase & Co.
  • On 5/23/2019 Richard F Pops, Director, sold 110,000 with an average share price of $24.88 per share and the total transaction amounting to $2,736,800.00.
  • On 5/22/2019 Michael J Landine, SVP, sold 20,000 with an average share price of $24.93 per share and the total transaction amounting to $498,600.00.
  • On 5/16/2019 Richard F Pops, CEO, sold 60,000 with an average share price of $25.42 per share and the total transaction amounting to $1,525,200.00.
  • On 5/9/2019 David Joseph Gaffin, SVP, sold 5,373 with an average share price of $26.89 per share and the total transaction amounting to $144,479.97.
  • On 4/1/2019 Paul J Mitchell, Director, sold 1,000 with an average share price of $36.64 per share and the total transaction amounting to $36,640.00.
  • On 3/14/2019 Michael J Landine, SVP, sold 25,000 with an average share price of $33.05 per share and the total transaction amounting to $826,250.00.
  • On 3/13/2019 Richard F Pops, Director, sold 60,000 with an average share price of $33.32 per share and the total transaction amounting to $1,999,200.00.

About Alkermes Plc (NASDAQ:ALKS)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. Read More…

Recent Trading Activity for Alkermes Plc (NASDAQ:ALKS)
Shares of Alkermes Plc closed the previous trading session at 22.53 −0.41 1.79% with shares trading hands.